Edition:
United Kingdom

Aspen Pharmacare Holdings Ltd (APNJ.J)

APNJ.J on Johannesburg Stock Exchange

26,151.80ZAc
16 Aug 2018
Change (% chg)

207.80 (+0.80%)
Prev Close
25,944.00
Open
25,960.00
Day's High
26,444.00
Day's Low
25,875.00
Volume
1,218,552
Avg. Vol
957,139
52-wk High
32,750.00
52-wk Low
22,987.00

Select another date:

Thu, May 17 2018

South African drugmaker Aspen secures 3.4 billion euro credit line

JOHANNESBURG, May 17 Aspen Pharmacare, Africa's biggest generic drugmaker, said on Thursday it had secured a 3.4 billion euro ($4 billion) credit facility for refinancing debt at three of its subsidiaries.

Aspen expands revenue-boosting therapeutic unit with new $80 million plant

PORT ELIZABETH, South Africa South African drug maker Aspen Pharmacare will produce up to 3.6 billion pills a year at its new manufacturing plant as it expands its therapeutic portfolio, Chief Executive Stephen Saad said on Monday at the official launch.

Aspen expands revenue-boosting therapeutic unit with new $80 million plant

PORT ELIZABETH, South Africa, May 7 South African drug maker Aspen Pharmacare will produce up to 3.6 billion pills a year at its new manufacturing plant as it expands its therapeutic portfolio, Chief Executive Stephen Saad said on Monday at the official launch.

Aspen Pharma may expand infant milk business into Saudi Arabia

JOHANNESBURG Aspen Pharmacare is looking to expand its infant milk formula business into Saudi Arabia, its deputy chief executive said after the company reported a 26 percent rise in first-half profit.

Aspen Pharmacare eyes Saudi Arabia to expand infant milk business

JOHANNESBURG, March 8 South Africa's Aspen Pharmacare is looking to expand its infant milk formula business into Saudi Arabia, its deputy Chief Executive said on Thursday, as the pharmaceutical company seeks to grow its brand presence in the Middle-East.

Therapeutic brands help lift Aspen Pharmacare's H1 profit

JOHANNESBURG, March 8 South Africa's Aspen Pharmacare said on Thursday first-half earnings rose 26 percent, buoyed by a strong result from therapeutic focused brands.

BRIEF-Aspen Pharmacare Says HY ‍Normalised HEPS Increased By 26 Pct

* ‍NORMALISED HEADLINE EARNINGS PER SHARE INCREASED BY 26% TO 872 CENTS FOR SIX MONTHS ENDED 31 DECEMBER 2017​

Select another date: